Ben Toogood

Ben Toogood is an experienced professional who currently holds positions as the Chief Executive Officer at invoX Pharma Limited, Board Member at pHion Therapeutics, and Board Member at Karolinska Development. Ben's previous roles include Head Global BD and M&A Sandoz at Novartis, Group New Business Development Executive at Aspen Pharma Group, and Vice President Of Global Business Development at Pharmathen. Ben has a BPharm from Rhodes University and an Executive MBA in Management from the University of Cambridge.